Mark Watson
Merck & Co.
4 Papers
Mark Watson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Population & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group
D C Anderson,Baltazar Gomez-Mancilla,B B Spear,D M Barnes,K Cheeseman,Peter M. Shaw,J Friedman,A McCarthy,Celia Brazell,SC Ray,Duncan McHale,Lara Hashimoto,R Sandbrink,Mark Watson,Ronald A Salerno,Nadine Cohen,CE Lister +16 more
TL;DR: Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.
56
Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
A. Pereslete,Ahmad Ozair,Atulya A. Khosla,Shreyas Bellur,C. Hurmiz,Suresh Marada,Mark Watson,Manmeet Ahluwalia +7 more
TL;DR: In this article , racial and ethnic disparities have been demonstrated to be widespread in lung cancer, including in the US, despite insurance coverage for standard biomarker testing, testing rates remain low in minority populations.
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Jacques Fellay,Alexander J. Thompson,Dongliang Ge,Curtis Gumbs,Thomas J. Urban,Kevin V. Shianna,Latasha Little,Ping Qiu,Arthur H. Bertelsen,Mark Watson,Amelia Wall Warner,Andrew J. Muir,Clifford A. Brass,Janice K. Albrecht,Mark S. Sulkowski,John G. McHutchison,David Goldstein +16 more
TL;DR: It is shown that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
Lawrence J. Lesko,Ronald A Salerno,Brian B Spear,Donald C. Anderson,Timothy Anderson,Celia Brazell,Jerry M. Collins,Andrew J Dorner,David M. Essayan,Baltazar Gomez-Mancilla,Joseph L. Hackett,Shiew-Mei Huang,Susan Ide,Joanne M. Killinger,John K. Leighton,Elizabeth Mansfield,Robert J. Meyer,Stephen G Ryan,Virginia D. Schmith,Peter M. Shaw,Frank D. Sistare,Mark Watson,Alexandra Worobec +22 more
TL;DR: The specific aim of the workshop was to identify key issues associated with the application of pharmacogenetics and pharmacogenomics, including the feasibility of a regulatory “safe harbor” for exploratory genome‐based data, and to provide a forum for industry‐regulatory agency dialogue on these important issues.